Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ALG.APV-527 |
| Synonyms | |
| Therapy Description |
ALG.APV-527 is a bispecific antibody that targets TNFRSF9 (4-1BB) and 5T4 (TPBG), which potentially leads to enhanced antitumor immune response and inhibition of tumor growth (PMID: 36343381). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ALG.APV-527 | ALG.APV527|ALG.APV 527 | TNFRSF9 Antibody 36 | ALG.APV-527 is a bispecific antibody that targets TNFRSF9 (4-1BB) and 5T4 (TPBG), which potentially leads to enhanced antitumor immune response and inhibition of tumor growth (PMID: 36343381). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Unknown status | USA | 0 |